Clinical Trial

A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-01 (NCT06291961),No investigational drug product will be administered in the study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-01.
Trial Details
NCT Number NCT06717932
Lead Sponsor CorrectSequence Therapeutics Co., Ltd
Conditions Beta-Thalassemia
Enrollment 8 participants
Start Date 2025-05-15
Primary Completion 2039-11 (estimated)
Study Completion 2039-11 (estimated)
Updated on ClinicalTrials.gov 2026-02-10